by James Lyons-Weiler, PhD, Popular Rationalism, ©2025
(Sep. 22, 2025) — The federal government just signaled a serious course correction on autism. In a joint appearance that felt less like a press conference and more like a policy pivot, President Donald J. Trump stood alongside HHS Secretary Robert F. Kennedy, Jr., NIH Director Jay Bhattacharya, FDA Commissioner Marty Makary, and CMS Director Mehmet Oz to outline an all-agency plan that treats autism as an urgent, tractable public-health crisis—not a career-long grant treadmill.
The package is sweeping. It elevates environmental and pharmaceutical exposures to first-class research questions, directs label changes with clinical relevance, and begins to dismantle sacred cows that have stifled honest inquiry for a generation.
Trump led with the cultural taboo: acetaminophen. He urged that during pregnancy it be used “only when medically necessary,” warned against reflexive dosing of children “every time they receive a vaccine,” and linked these positions to rising rates of autism that have “destroyed families” and imposed massive social costs. He also called for smaller vaccine doses on a more spread-out schedule, and he previewed a CDC policy modernization: the separation of MMRV into its component measles, mumps, rubella, and varicella vaccinations. He called ending the routine HepB birth dose a “revolution,” arguing that a sexually transmitted infection does not justify a blanket neonatal exposure.
Kennedy matched that candor point for point. He called the decades-long fixation on “the genetics of autism” fruitless by design, the equivalent of studying lung-cancer genomes while banning the word “cigarettes.” He announced that HHS will move on acetaminophen: FDA will require safety-label changes on acetaminophen-containing products, with specific caution in pregnancy and prudent use in children. He insisted on the “lowest effective dose” standards and promised a series of follow-on reports that will examine all plausible contributors—vaccines included—with “no taboos.” Mothers will not be gaslit. The period of neglect is over.
From Rhetoric to Levers
Makary put FDA’s levers on the table. He announced updated labeling requirements for acetaminophen. He referenced major cohort and pooled analyses—Boston Birth Cohort, Nurses’ Health Study, and a Mount Sinai review/meta-analysis—describing the totality of evidence as consistent with causal signals for prenatal acetaminophen and neurodevelopmental outcomes, including autism. He challenged the “mindless” fever-suppression reflex that dominates pediatric practice, even noting evidence that treating fever may prolong illness in young children because fever serves a host-defense function. This is what regulatory science looks like when it remembers physiology.
Makary also announced a label change with immediate bedside implications: prescription leucovorin (folinic acid). He summarized the evidence that a subset of autistic children exhibit autoimmunity to folate receptors in the brain and reported response rates as high as two in three in studies where leucovorin was used to address cerebral folate deficiency. That label change matters because it tells clinicians: you have a defined pathway to try, with guardrails.
Oz then did something rare for CMS: he connected reimbursement to real-world evidence generation. CMS will issue guidance to states to ensure coverage and to capture outcomes data on leucovorin as the first FDA-recognized treatment pathway in autism. He cited a five-fold increase in autism diagnoses as reason enough to stop waiting for perfect RCTs before supporting access. Coverage with learning loops—long overdue.
NIH: From Slogans to Study Designs
Bhattacharya described imminent awards under the Autism Data Science Initiative—thirteen grants that foreground Exposomics to reflect the reality that autism arises from interacting factors, not single-gene myths. He emphasized collaboration with FDA and CMS to align discovery with regulation and reimbursement so that findings cross the translational canyon. In short: design the portfolio to answer questions that matter in clinics and courts, not just in tenure files.
Vaccines: Dose, Timing, Composition
Trump pressed for recalibration: smaller doses, wider spacing, component vaccines instead of combination defaults, and an end to the rote HepB birth dose. He added a plain-spoken prompt to new parents—“When you have a baby, don’t give your baby Tylenol. At all.”—and he questioned why the pediatric vaccine schedule has expanded so aggressively. He raised the obvious political economy: profits and workflow convenience. Expect blowback. Also expect long-suppressed questions—about adjuvants, cumulative aluminum exposure, and risk stratification—to finally get oxygen.
Read the rest here.